Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Trial Profile

Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms NEOPAX001
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 May 2017 Status changed from recruiting to completed.
    • 23 Aug 2014 Status changed from not yet recruiting to recruiting, as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top